ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

resmetirom

Also written as “Resmetirom”, “MGL-3196” and “VIA-3196”.

Its studies are mostly in Non-alcoholic Fatty Liver Disease · Fatty Liver · Liver Diseases · Fibrosis · Liver Cirrhosis, led by 3 companies.

Drug pageResmetirom: every studyAll 23 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Aug 25, 202622 company-led studies, 8 open or runningNext primary completion: Dec 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Madrigal Pharmaceuticalsits history only207 open or runningphase 4since Aug 25, 2026Jun 2, 2011Dec 2026phase 3 · NCT05500222
Nabiqasim Industries (Pvt)its history only11 open or runningphase 4since Nov 18, 2025Nov 18, 2025none ahead
Sagimet Biosciences10 open or runningphase 1since Oct 8, 2025Oct 8, 2025none ahead

Also a collaborator on its studies: Celerion.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Sagimet Biosciences only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Jun 9, 2018Named resmetiromINNProposed as its International Nonproprietary Name in WHO's List 119 · before, MGL-3196, VIA-3196
  2. Oct 8, 2025First study: phase 1 study in HealthyFirst studyNCT07216313 · 40 enrolled · United States

TargetBeta

THRB →read by rule
“Thyroid hormone receptor beta-1 agonist”ChEMBL 37, by rule

Other programs on THRB

ProgramCompanyFurthest phaseStudies
KYLO-0603Sino Biopharmaceuticalphase 22
CG-0416rulehongkong-curegene-innovation-co-limitedphase 11
KPC000154rulekunming-pharmaceuticals-incphase 11

Studies

The one study Sagimet Biosciences leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07216313Healthy · United States1CompletedOct 20, 202540

How it is read

Names in the registry

  • “Resmetirom”, 9 entries
  • “MGL-3196”, 8 entries
  • “VIA-3196”, 2 entries
  • “Rezdiffra”, 1 entry
  • “MGL-3196 (resmetirom)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.